Literature DB >> 31338179

Cost reduction as a result of bortezomib vial sharing in the University Hospital Center 'Mother Theresa' Tirana.

Florjana Rustemi1, Ledjan Malaj2, Ela Hoti2, Enida Balla3.   

Abstract

Keywords:  clinical pharmacy; compounding (individualised preparation); health economics; myeloma; pharmacoeconomics

Year:  2018        PMID： 31338179      PMCID： PMC6613912          DOI： 10.1136/ejhpharm-2018-001676

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN： 2047-9956


× No keyword cloud information.
  3 in total

1.  Ideal vial size for bortezomib: real-world data on waste and cost reduction in treatment of multiple myeloma in Brazil.

Authors:  Luciana Clark; Ana Paula Castro; Anna Flávia Fortes; Fábio Santos; Otávio Clark; Tobias Engel; Bruna Pegoretti; Vanessa Teich; Denizar Vianna; Fabíola Puty
Journal:  Value Health       Date:  2011 Jul-Aug       Impact factor: 5.725

Review 2.  Economic and clinical impact of multiple myeloma to managed care.

Authors:  Richard Cook
Journal:  J Manag Care Pharm       Date:  2008-09

3.  Drug waste minimisation and cost-containment in Medical Oncology: two-year results of a feasibility study.

Authors:  Gianpiero Fasola; Marianna Aita; Luisa Marini; Alessandro Follador; Marina Tosolini; Laura Mattioni; Mauro Mansutti; Andrea Piga; Silvio Brusaferro; Giuseppe Aprile
Journal:  BMC Health Serv Res       Date:  2008-04-01       Impact factor: 2.655
  3 in total
  1 in total

1.  Economics of alternative dosing strategies for pembrolizumab and nivolumab at a single academic cancer center.

Authors:  Evan Hall; Jenny Zhang; Eun Jeong Kim; Grace Hwang; Gilbert Chu; Shailender Bhatia; Sunil Reddy
Journal:  Cancer Med       Date:  2020-01-28       Impact factor: 4.452
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.